Cargando…

The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections

OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shixiao, Qin, Jiajia, Zhou, Peng, Peng, Minfei, Qian, Jiao, Cai, Yingying, Shi, Qingxin, Tung, Tao-Hsin, Shen, Bo, Yu, Sufei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801411/
https://www.ncbi.nlm.nih.gov/pubmed/36590589
http://dx.doi.org/10.3389/fcimb.2022.961746
_version_ 1784861492064026624
author Li, Shixiao
Qin, Jiajia
Zhou, Peng
Peng, Minfei
Qian, Jiao
Cai, Yingying
Shi, Qingxin
Tung, Tao-Hsin
Shen, Bo
Yu, Sufei
author_facet Li, Shixiao
Qin, Jiajia
Zhou, Peng
Peng, Minfei
Qian, Jiao
Cai, Yingying
Shi, Qingxin
Tung, Tao-Hsin
Shen, Bo
Yu, Sufei
author_sort Li, Shixiao
collection PubMed
description OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) remain scarce. METHODS: A total of 306 patients with suspected LRTIs were enrolled from January 2019 to December 2021. The diagnostic performance of conventional methods and mNGS on bronchoalveolar lavage fluid (BALF) were compared. BALF mNGS was performed using a commercial and an in-house laboratory. The diagnostic value and the clinical implications of mNGS for LRTIs were analyzed for the different platforms. RESULTS: The positive rate of mNGS in the in-house group was higher than that in the commercial group (85.26% vs. 70.67%, p < 0.001). mNGS significantly increased the pathogen detection rate compared with conventional methods [from 70.67% vs. 22.67% (p < 0.001) to 85.26% vs. 30.77% (p < 0.001)]. The pathogens detected using mNGS included bacteria, fungi, viruses, and atypical pathogens. The in-house platform performed well on a wider spectrum of microbial distribution. Furthermore, it showed an advantage in detecting mixed pathogens in immunocompromised patients. Among the mNGS positive cases, 34 (32.0%) cases had their antibiotics adjusted in the commercial group, while 51 (38.3%) cases had a change of treatment in the in-house group. Moreover, the turnaround time of mNGS and the time from mNGS to discharge in the in-house group were significantly shorter than those in the commercial group. CONCLUSION: In-house mNGS had a higher detection rate and can show a wider spectrum of pathogens, with potential benefits for the clinic by shortening the turnaround time and hospitalization, and it may be more suitable for clinical microbiology laboratories.
format Online
Article
Text
id pubmed-9801411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98014112022-12-31 The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections Li, Shixiao Qin, Jiajia Zhou, Peng Peng, Minfei Qian, Jiao Cai, Yingying Shi, Qingxin Tung, Tao-Hsin Shen, Bo Yu, Sufei Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVE: Metagenomic next-generation sequencing (mNGS) technology has the potential to detect a wide range of pathogenic microorganisms. However, reports on the diagnostic value and clinical significance of different platforms of mNGS for patients with lower respiratory tract infections (LRTIs) remain scarce. METHODS: A total of 306 patients with suspected LRTIs were enrolled from January 2019 to December 2021. The diagnostic performance of conventional methods and mNGS on bronchoalveolar lavage fluid (BALF) were compared. BALF mNGS was performed using a commercial and an in-house laboratory. The diagnostic value and the clinical implications of mNGS for LRTIs were analyzed for the different platforms. RESULTS: The positive rate of mNGS in the in-house group was higher than that in the commercial group (85.26% vs. 70.67%, p < 0.001). mNGS significantly increased the pathogen detection rate compared with conventional methods [from 70.67% vs. 22.67% (p < 0.001) to 85.26% vs. 30.77% (p < 0.001)]. The pathogens detected using mNGS included bacteria, fungi, viruses, and atypical pathogens. The in-house platform performed well on a wider spectrum of microbial distribution. Furthermore, it showed an advantage in detecting mixed pathogens in immunocompromised patients. Among the mNGS positive cases, 34 (32.0%) cases had their antibiotics adjusted in the commercial group, while 51 (38.3%) cases had a change of treatment in the in-house group. Moreover, the turnaround time of mNGS and the time from mNGS to discharge in the in-house group were significantly shorter than those in the commercial group. CONCLUSION: In-house mNGS had a higher detection rate and can show a wider spectrum of pathogens, with potential benefits for the clinic by shortening the turnaround time and hospitalization, and it may be more suitable for clinical microbiology laboratories. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9801411/ /pubmed/36590589 http://dx.doi.org/10.3389/fcimb.2022.961746 Text en Copyright © 2022 Li, Qin, Zhou, Peng, Qian, Cai, Shi, Tung, Shen and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Li, Shixiao
Qin, Jiajia
Zhou, Peng
Peng, Minfei
Qian, Jiao
Cai, Yingying
Shi, Qingxin
Tung, Tao-Hsin
Shen, Bo
Yu, Sufei
The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title_full The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title_fullStr The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title_full_unstemmed The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title_short The clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
title_sort clinical significance of in-house metagenomic next-generation sequencing for bronchoalveolar lavage fluid diagnostics in patients with lower respiratory tract infections
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801411/
https://www.ncbi.nlm.nih.gov/pubmed/36590589
http://dx.doi.org/10.3389/fcimb.2022.961746
work_keys_str_mv AT lishixiao theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT qinjiajia theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT zhoupeng theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT pengminfei theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT qianjiao theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT caiyingying theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT shiqingxin theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT tungtaohsin theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT shenbo theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT yusufei theclinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT lishixiao clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT qinjiajia clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT zhoupeng clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT pengminfei clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT qianjiao clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT caiyingying clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT shiqingxin clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT tungtaohsin clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT shenbo clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections
AT yusufei clinicalsignificanceofinhousemetagenomicnextgenerationsequencingforbronchoalveolarlavagefluiddiagnosticsinpatientswithlowerrespiratorytractinfections